%20-%20http://www.bohemiancoding.com/sketch%20--%3e%3ctitle%3eIcon/Menu%3c/title%3e%3cdesc%3eCreated%20with%20Sketch.%3c/desc%3e%3cdefs%3e%3cpolygon%20id='path-1'%20points='0.0005%200.646%2022.386%200.646%2022.386%203.1455%200.0005%203.1455'%3e%3c/polygon%3e%3cpolygon%20id='path-3'%20points='0.0005%200.9341%2022.386%200.9341%2022.386%203.4341%200.0005%203.4341'%3e%3c/polygon%3e%3cpolygon%20id='path-5'%20points='0.0005%200.5%2022.386%200.5%2022.386%203%200.0005%203'%3e%3c/polygon%3e%3c/defs%3e%3cg%20id='Symbols'%20stroke='none'%20stroke-width='1'%20fill='none'%20fill-rule='evenodd'%3e%3cg%20id='Icon/Menu'%3e%3cg%20id='Group-10-Copy'%20transform='translate(3.800000,%205.300000)'%3e%3cg%20id='Group-3'%20transform='translate(0.000000,%200.354500)'%3e%3cmask%20id='mask-2'%20fill='white'%3e%3cuse%20xlink:href='%23path-1'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-2'%3e%3c/g%3e%3cpath%20d='M22.3865,2.6455%20C22.3865,2.9205%2022.1615,3.1455%2021.8865,3.1455%20L0.5005,3.1455%20C0.2245,3.1455%200.0005,2.9205%200.0005,2.6455%20L0.0005,1.1455%20C0.0005,0.8705%200.2245,0.6455%200.5005,0.6455%20L21.8865,0.6455%20C22.1615,0.6455%2022.3865,0.8705%2022.3865,1.1455%20L22.3865,2.6455%20Z'%20id='Fill-1'%20fill='%23FFFFFF'%20mask='url(%23mask-2)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-6'%20transform='translate(0.000000,%207.354500)'%3e%3cmask%20id='mask-4'%20fill='white'%3e%3cuse%20xlink:href='%23path-3'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-5'%3e%3c/g%3e%3cpath%20d='M22.3865,2.9341%20C22.3865,3.2091%2022.1615,3.4341%2021.8865,3.4341%20L0.5005,3.4341%20C0.2245,3.4341%200.0005,3.2091%200.0005,2.9341%20L0.0005,1.4341%20C0.0005,1.1591%200.2245,0.9341%200.5005,0.9341%20L21.8865,0.9341%20C22.1615,0.9341%2022.3865,1.1591%2022.3865,1.4341%20L22.3865,2.9341%20Z'%20id='Fill-4'%20fill='%23FFFFFF'%20mask='url(%23mask-4)'%3e%3c/path%3e%3c/g%3e%3cg%20id='Group-9'%20transform='translate(0.000000,%2015.354500)'%3e%3cmask%20id='mask-6'%20fill='white'%3e%3cuse%20xlink:href='%23path-5'%3e%3c/use%3e%3c/mask%3e%3cg%20id='Clip-8'%3e%3c/g%3e%3cpath%20d='M22.3865,2.5%20C22.3865,2.775%2022.1615,3%2021.8865,3%20L0.5005,3%20C0.2245,3%200.0005,2.775%200.0005,2.5%20L0.0005,1%20C0.0005,0.725%200.2245,0.5%200.5005,0.5%20L21.8865,0.5%20C22.1615,0.5%2022.3865,0.725%2022.3865,1%20L22.3865,2.5%20Z'%20id='Fill-7'%20fill='%23FFFFFF'%20mask='url(%23mask-6)'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23fff'%20fill-rule='nonzero'%3e%3cg%20id='icon/fold'%20transform='translate(240.000000,%20272.000000)'%3e%3cpath%20d='M11.5,2.3%20C6.4216,2.3%202.3,6.4216%202.3,11.5%20C2.3,16.5784%206.4216,20.7%2011.5,20.7%20C16.5784,20.7%2020.7,16.5784%2020.7,11.5%20C20.7,6.4216%2016.5784,2.3%2011.5,2.3%20Z%20M10.58,18.7956%20C6.946,18.3448%204.14,15.2536%204.14,11.5%20C4.14,10.9296%204.2136,10.3868%204.3332,9.8532%20L8.74,14.26%20L8.74,15.18%20C8.74,16.192%209.568,17.02%2010.58,17.02%20L10.58,18.7956%20Z%20M16.928,16.4588%20C16.6888,15.7136%2016.008,15.18%2015.18,15.18%20L14.26,15.18%20L14.26,12.42%20C14.26,11.914%2013.846,11.5%2013.34,11.5%20L7.82,11.5%20L7.82,9.66%20L9.66,9.66%20C10.166,9.66%2010.58,9.246%2010.58,8.74%20L10.58,6.9%20L12.42,6.9%20C13.432,6.9%2014.26,6.072%2014.26,5.06%20L14.26,4.6828%20C16.9556,5.7776%2018.86,8.418%2018.86,11.5%20C18.86,13.4136%2018.124,15.1524%2016.928,16.4588%20Z'%20id='形状'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
媒体文章
了解权威媒体如何报道药明康德赋能医药健康产业的专题文章、访谈，从第三方视角，展现药明康德的CRDMO能力与对全球生命科学创新的贡献。
了解权威媒体如何报道药明康德赋能医药健康产业的专题文章、访谈，从第三方视角，展现药明康德的CRDMO能力与对全球生命科学创新的贡献。
筛选
全部年份
2026/04/07
媒体声音｜探访瑞士库威基地：CRDMO模式如何加速全球创新转化？
近日，药明康德高级副总裁，制剂研发和生产业务部负责人陈金玲博士接受了德国媒体VC Magazin专访。作为深耕行业二十余年的资深专家，陈博士深入解读了CRDMO模式的价值，并分享了瑞士库威基地如何构建稳健的能力体系，以高效应对复杂研发挑战。
阅读更多2025/10/30
媒体声音 | 药明康德一体化CRDMO如何助力欧洲创新发展
近日，药明康德高级副总裁，小分子原料药后期和商业化项目业务部负责人陈珂博士接受了德国行业媒体CHEManager的专访。陈珂博士在有机合成化学、原料药工艺研发与生产以及新药CMC等领域拥有十多年的行业经验。她分享了自己对于行业发展和区域创新的洞见，并介绍了像药明康德这样的全球合作伙伴如何赋能欧洲乃至全球客户，推动创新生态圈的发展。
阅读更多2025/09/23
媒体声音 | 药明康德一体化CRDMO如何助力北欧创新发展？
近日，药明康德新药发现业务副总裁Dave Madge博士接受欧洲行业媒体《北欧生命科学新闻》（Nordic Life Science News）的采访，他为斯堪的纳维亚半岛地区的创新活力而感到振奋，也提到，无论是初创企业，还是大型制药公司，药明康德的一体化CRDMO平台都能为他们创造价值，助力当地创新生态圈的发展。
阅读更多2025/09/01
对话陈民章博士：25年来，药明康德如何加速新药诞生？
在药明康德成立25周年之际，陈民章博士应邀接受知名产业媒体BioWorld专访，回顾公司的发展历程，并分享药明康德独特的CRDMO业务模式如何为生物医药行业的客户们降低研发门槛，提升研发效率，为全球病患带来突破性的治疗方案。
阅读更多2025/08/22
25载平台之路，Co-CEO陈民章博士谈药明康德如何赋能产业创新
日前，行业媒体Pharma Manufacturing的主编Greg Slabodkin采访了公司联席首席执行官陈民章博士。陈民章博士拥有二十多年新药研发和生产管理经验，在多个全球新药的研发及商业化过程中发挥了重要作用。
阅读更多